Trial reportThe Journal of infectious diseases2015
Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.
Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Pooled it
- Article
- Article
- Analysis of inpatient complications in HIV/AIDS patients undergoing total hip arthroplasty - A propensity matched cohort study.Journal of clinical orthopaedics and trauma · 2023Article
- Surrogate Biomarkers of Disease Progression in Human Pegivirus Seropositive Human Immunodeficiency Virus-Infected Individuals.Viral immunology · 2023Article
- Plasma virome dynamics in chronic hepatitis B virus infected patients.Frontiers in microbiology · 2023Article
- Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.Virulence · 2022Review
- Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?Frontiers in immunology · 2022Review
- Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.Virology journal · 2021Article
- Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil.Virology journal · 2020Article
- Clinical relevance of plasma virome dynamics in liver transplant recipients.EBioMedicine · 2020Article
- Human Hepegivirus-1: Innocent Traveler, Helpful Symbiote, or Insidious Pathogen?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Viral Infections, the Microbiome, and Probiotics.Frontiers in cellular and infection microbiology · 2020Review
- Human Pegivirus infection and lymphoma risk and prognosis: a North American study.British journal of haematology · 2018Article
- Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV.Journal of medical virology · 2017Article
- Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection.PLoS pathogens · 2017Article
- High HPgV replication is associated with improved surrogate markers of HIV progression.PloS one · 2017Article
- Arteriviruses, Pegiviruses, and Lentiviruses Are Common among Wild African Monkeys.Journal of virology · 2016Article
- Research on the human virome: where are we and what is next.Microbiome · 2016Article
- GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAn association between GB virus C (GBV-C) and improved outcomes of human immunodeficiency virus (HIV) infection has been reported in HIV-positive individuals with active GBV-C coinfection. This study provides insights into the immune mechanisms underlying the protective role of GBV-C in HIV-infected patients.
methodsThe concentrations of 64 cytokines and chemokines were measured in plasma samples obtained from the Viral Activation Transfusion Study cohort before transfusion and longitudinally from 30 patients positive for both HIV and GBV-C (hereafter, "cases") and 30 patients positive for HIV and negative for GBV-C (hereafter, "controls").
resultsCases had lower HIV viral loads and higher CD4 T-cell counts than controls after acquisition of GBV-C infection. Most of the modulated cytokines and chemokines were reduced after GBV-C detection, including many proinflammatory cytokines, suggesting an overall antiinflammatory effect of GBV-C in HIV-positive subjects. Most pathways and functions of the measured cytokines were downregulated in cases, except cell death pathways, which were upregulated in various cell subsets in the 3 months after GBV-C detection.
conclusionsGBV-C has a protective effect, in part through a competition mechanism leading to decreased inflammation and improved HIV disease outcome in cases. Further studies are necessary to establish whether GBV-C may have deleterious effects on the host at the cellular level, including depleting the cells that are the targets of HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.